Literature DB >> 10779181

Effects of betahistine metabolites on frog ampullar receptors.

L Botta1, E Mira, S Valli, G Zucca, P Perin, C Benvenuti, A Fossati, P Valli.   

Abstract

Previous studies have demonstrated that betahistine, an histamine-like substance used widely as an anti-vertigo drug, can decrease ampullar receptor resting discharge without affecting their mechanically evoked responses. Pharmacokinetic studies have shown that this drug is transformed, mainly at the hepatic level, into aminoethylpyridine (M1), hydroxyethylpyridine (M2), then excreted with the urine as pyridylacetic acid (M3). The goal of the present study was to investigate whether betahistine metabolites are also able to affect vestibular receptor activity. Results demonstrated that, in the range tested (10(-7)-10(-2) M), M2 and M3 exerted no effect, whereas M1, at concentrations higher than 10(-6) M, was able to reduce the resting discharge of ampullar receptors without affecting the evoked responses. M1 therefore exerts effects similar to those of betahistine on ampullar receptors. This might be of some clinical interest. On the basis of our data, the hypothesis may be put forward that the anti-vertigo action of betahistine is at first achieved by betahistine itself and then sustained by M1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779181     DOI: 10.1080/000164800760370783

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  3 in total

1.  Meta-analysis of clinical studies with betahistine in Ménière's disease and vestibular vertigo.

Authors:  Jozef J P Nauta
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-06-19       Impact factor: 2.503

2.  Neuropharmacology of vestibular system disorders.

Authors:  Enrique Soto; Rosario Vega
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

3.  Good Clinical Approach: Delphi Consensus for the Use of Betahistine in Menière's Disease.

Authors:  Augusto Pietro Casani; Elena Navari; Giorgio Guidetti; Michel Lacour
Journal:  Int J Otolaryngol       Date:  2018-10-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.